Online inquiry

IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12399MR)

This product GTTS-WQ12399MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Crohn's disease (CD), Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12399MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10735MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ3324MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ184MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ1625MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ7240MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ9065MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ3365MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW